Thu, Apr 25, 2024
Syngene International's profit after tax (PAT) was up by 5.6 per cent to Rs 189 core against Rs 179 crore Year-on-Year (YoY). The company's revenue from operations slipped by 7.70 per cent to Rs 917 crore compared to Rs 994 crore YoY. Its EBITDA was up by a mere 0.95 per cent to Rs 317 crore against Rs 314 crore a year ago.
More >
Wed, Oct 18, 2023
CorporateRadar, Demand trend of large pharma strong, Demand trend of small pharma will improve in 1-2 quarters. Acquired Stelis Biopharma last quarter, Mahesh Bhalgat. Watch Swati Khandewal's exclusive conversation with Mahesh Bhalgat, COO of Syngene International.
Thu, Jul 27, 2023
Due to strong demand, expect good performance in future, will spend funds on new acquisitions, capacity expansion: Dr. Mahesh Bhalgat, COO, Syngene International
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.